The ODM DUR Board meeting was called to order at 12:00 PM EST in room C621
50 West Town Street, Columbus, Ohio. Michael Dietz, D.O. presided.

The following Board members were present:
Michelle Barger, Pharm.D.
David Brookover, R.Ph.
Michael Dietz, D.O., Chair
Robert Kubasak, R.Ph.
A. Mehran Mostafavifar, M.D.
Michael Farrell, M.D.
Stacey Rexrode-Brewer, Pharm.D., Co-Chair
Donald Sullivan, Ph.D., R.Ph.

Also present from ODM were Tracey Archibald, Pharm.D., Scott Baran, R.Ph., Sean Eckard, B.S. Pharm. D.
Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm. D., Gail Master, R.Ph., and Philip
Verret, Pharm.D. Approximately 25 observers were present.

Conflict of Interest statements were distributed, signed, and collected.

Roll Call and Review of Previous Minutes

The November 12, 2019 DUR Board Meeting Minutes were approved.

DUR Committee Report

G. Master presented an update on the opioid and benzodiazepine intervention. This intervention will be
re-reviewed in six months. The DUR Board requested information about the percentage of cancer patients
as well as the percent of members who are new starts on this combination of medications.
G. Master presented the re-review results from the intervention directed at the prescribers of patients who
were not adherent to their antidiabetic medications (non-insulin).

Next, G. Master reviewed the SUPPORT Act. She described reviews of profiles for members less than 18
years old taking two atypical antipsychotics, and a review of those taking four or more psychotropic drugs.
She also described profile reviews for members taking opioids and antipsychotics. An educational mailing
will be directed to prescribers of antipsychotic medications for pediatric patients to ensure they are
performing metabolic monitoring and are re-evaluating for adverse effects.

Lastly, G. Master provided an update to the Board on the Coordinated Services Program (CSP) membership.
There are currently 211 Fee for Service members are enrolled in the program.

Health Plan Policy Update

M. Barger announced that the Unified Preferred Drug List went into effect on January 1st, 2020. ODM
continues to collaborate with their Managed Care Plans to help ensure a successful transition.
Next, results from the Annual CMS DUR Report are now available at the medicaid.gov website. These
reports are broken down into a National State Comparison/Summary Report as well as State Fee-For-Service Individual Reports.

ODM submitted the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act State Plan Amendment to CMS, also referred to as the SUPPORT Act SPA. Also, this year ODM will be conducting the Cost of Dispensing Survey. The department administers this survey every two years to ODM enrolled pharmacies, and a final report is generated. The final report will be posted on the Medicaid Pharmacy website.

And lastly, ODM is in the process of selecting a Single Pharmacy Benefit Manager to be used by all Ohio Medicaid Managed Care Plans. This is currently in process and more updates will be made available during future meetings.

Unfinished Business

G. Master informed the Board that the Prescriber Benchmark Cards are still under review and she will present it to the Board when more information is available.

New Business

G. Master provided an overview of an adherence intervention directed at prescribers of antiepileptic medications for patients who are less than 70% compliant with their medication. The Board reviewed the letter.

T. Archibald presented a summary of oncology medications processing through the FFS pharmacy benefit. She requested the Board consider allowing a Clinical Review prior to claims processing. The purpose of this request is to assure appropriate use and safeguard against experimental use. Discussion ensued around the prior authorization and appeals process. T. Archibald noted that Fee for Service is the outlier by not requiring the clinical review of the agents, and that the managed care plans require this presently. She informed the Board that members already taking these medications will be grandfathered and that once implemented, the process will be closely monitored.

G. Master mentioned that the Ohio State Board of Pharmacy is considering making gabapentin a controlled substance. If this occurs, the FFS Ohio Medicaid refill threshold on this medication will change from 80% to 90%. Discussion ensued around an opioid and gabapentin intervention. The Board voted to change the gabapentin refill threshold to 90%.

Announcements

The 2020 calendar was reviewed.
The September DUR Board meeting will be moved from September 15th to September 22nd, 2020.

The dates for the next DUR Board meetings were set as follows:

- May 12, 2020
- September 22, 2020
- November 10, 2020

Adjournment

The meeting was adjourned at 1:03 PM.